Skip to main content

Together we are beating cancer

Donate now

Immune-boosting vaccine helps body fight cancer

The Cancer Research UK logo
by Cancer Research UK | News

23 April 2009

0 comments 0 comments

CANCER RESEARCH UK-funded scientists have discovered that linking a molecule which initiates antibody production,to a ‘saboteur’ molecule, triggers the immune system to selectively destroy faulty cells. These findings published in Blood*, could potentially be used to selectively destroy tumour cells while ignoring healthy cells.

Mice were immunised with an antigen linked to a CpG ‘saboteur’ molecule. The antigen smuggled the CpG into specific cells to trigger the immune response system to produce antibodies that could potentially seek and destroy cancer cells.

The scientists demonstrated that mice immunised with different antigen-CpG** complexes had boosted antibody responses when compared with immunisation with the same antigen not linked to CpG. This demonstrated that the antigen was able to sneak CpG into the immune response hub of the cell.

This new strategy could be used for future cancer vaccination strategies – either through preventative medicine or cancer treatment – to stimulate specific immune responses against faulty proteins in tumour cells. The technique in effect supercharges the body’s immune system to help it fight cancer.

Lead author, Dr Facundo Batista, based at Cancer Research UK’s London Research Institute, said: “This technique allows antibodies to be produced to recognise very specific altered proteins in a tumour cell while ignoring the proteins in a healthy cell. This discovery reveals the potential in using the immune system to hunt down and destroy cancer cells. It gives us a route to make treatment as specific as possible.”

Dr Lesley Walker, Cancer Research UK’s director of science information, said: “There have already been exciting preliminary advances in treatment of lymphoma using antibodies which harness the body’s own immune response in a new way.

“This research is an important step in furthering Cancer Research UK’s role at the cutting edge of the development of effective therapies for cancer with fewer unpleasant side effects.”


For media enquiries please contact the press office on 020 7061 8300 or, out-of-hours, the duty press officer on 07050 264 059.